NORTH-WEST UNIVERSITY Patent applications |
Patent application number | Title | Published |
20160006355 | SWITCHED MODE DRIVE CIRCUIT - A switched mode drive circuit | 01-07-2016 |
20140370508 | A METHOD OF PREPARING BIOLOGICAL MATERIAL - This invention pertains to a method of preparing biological material from a biological sample selected from the group consisting of blood and sputum samples. The method includes the step of altering at least one constitutive characteristic of the biological sample in the presence of a capturing scaffold by adding a lysis buffer containing a solubilising agent and a detergent to the biological sample, for simultaneously inhibiting coagulation of the biological sample; lysing the biological sample to release the biological material from the biological sample, thus making the biological material available; and capturing at least one fraction of the biological material on the capturing scaffold. | 12-18-2014 |
20140255504 | ENHANCEMENT OF THE EFFICACY OF THERAPEUTIC PROTEINS - A formulation for administration of at least one therapeutic mammalian protein to a mammal or a protein selected from the group, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, comprising at least one therapeutic mammalian protein in a micro-emulsion comprising a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous or other pharmacologically acceptable carrier in which nitrous oxide is dissolved, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. A method for effective delivery of at least one therapeutic mammalian protein to a mammal and for enhancing the therapeutic efficacy of such at least one therapeutic mammalian protein, comprising the step of administering the at least one therapeutic mammalian protein to the mammal in such a formulation. | 09-11-2014 |
20140194288 | PLANT SUPPORT FORMULATION, VEHICLE FOR THE DELIVERY AND TRANSLOCATION OF PHYTOLOGICALLY BENEFICIAL SUBSTANCES AND COMPOSITIONS CONTAINING SAME - A plant supporting formulation which is also suitable for use as a delivery vehicle, or a component of a delivery vehicle, for the delivery of one or more phytologically beneficial substances to a plant, and for enhancing the translocation of such delivered substance(s) in or on the plant, the formulation comprising a micro-emulsion constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous carrier, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. The dispersion is preferably characterized in that at least 50% of the vesicles or microsponges are of a diametrical size of between 50 nm and 5 micrometer. The dispersion is further also characterized in that the micro-emulsion has a zeta potential of between −25 mV and −60 mV. | 07-10-2014 |
20140178431 | LIPID AND NITROUS OXIDE COMBINATION AS ADJUVANT FOR THE ENHANCEMENT OF THE EFFICACY OF VACCINES - The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5ω3], decosahexaenoic acid [C22: 6ω3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide. | 06-26-2014 |
20130344157 | ENHANCEMENT OF THE EFFICACY OF THERAPEUTIC PROTEINS - A formulation for administration of at least one therapeutic mammalian protein to a mammal or a protein selected from the group, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, comprising at least one therapeutic mammalian protein in a micro-emulsion comprising a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous or other pharmacologically acceptable carrier in which nitrous oxide is dissolved, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. A method for effective delivery of at least one therapeutic mammalian protein to a mammal and for enhancing the therapeutic efficacy of such at least one therapeutic mammalian protein, comprising the step of administering the at least one therapeutic mammalian protein to the mammal in such a formulation. | 12-26-2013 |
20130336990 | ENHANCEMENT OF THE ACTION OF ANTI-INFECTIVE AGENTS AND OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS AND TRANSPORTATION OF NUCLEIC ACID SUBSTANCES - The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism. The method is characterised in that the agent or nucleic acid substance is formulated with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20:5ω3], decosahexaenoic acid [C22:6ω3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide. The formulations of such agents or substances form part of the invention | 12-19-2013 |
20130224175 | RECOMBINANT THERAPEUTIC GLYCINE N-ACYLTRANSFERASE - This invention relates to a method of producing a recombinant enzyme, more particularly, this invention relates to a method of producing water soluble enzymatically active recombinant glycine N-acyltransferase (GLYAT (E.G. 2.1.3.13)), including the steps of providing a suitable expression host; preparing a vector including a gene for expressing GLYAT in the expression host to form an expression piasmid; transforming the host with the expression piasmid to form an expression system; expressing the GLYAT gene in the expression system; and separating the expressed GLYAT from the expression system. | 08-29-2013 |
20130176648 | POLE-SLIP PROTECTION SYSTEM AND METHOD FOR SYNCHRONOUS MACHINES - A method of protecting a synchronous machine ( | 07-11-2013 |
20130102550 | AMORPHOUS ROXITHROMYCIN COMPOSITION - This invention relates to a macrolide composition, more particularly an amorphous form (Form-III) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6-[(2S, 3R, 4S, 6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7, 12, 13-trihydroxy-4-[(2R, 4R, 5S, 6S)-5-hydroxy-4-methoxy-4, 6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxy-imino)-3, 5, 7, 9, 11, 13-hexamethyl-1-oxacyclotetradecan-2-one or roxithromycin characterised by the absence of peaks in the infra-red spectrum of amorphous (Form-III) of roxithromycin at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 relative to the infra-red spectrum of the prior art roxithromycin raw material displaying peaks at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 and further characterised by an increased solubility of at least 50% over prior art anhydrous and monohydrated roxithromycin in acetate buffer (pH 4.5), phosphate buffer (pH 6.8) and water. | 04-25-2013 |
20130072100 | AIR EXTRACTOR FROM A COCKPIT OF A CRAFT | 03-21-2013 |
20130059805 | COMPOSITION COMPRISING AN AMORPHOUS NON-CRYSTALLINE GLASS FORM OF AZITHROMYCIN - The invention relates to an amorphous non-crystalline glass form (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadec-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranoside or azithromycin having an infra-red pattern displaying characteristic relatively broad peaks at approximately 3500 and 1727 cm | 03-07-2013 |
20130045936 | COMPOSITION COMPRISING AN AMORPHOUS NON-CRYSTALLINE GLASS FORM OF ROXITHROMYCIN - The invention relates to an amorphous non-crystalline glass form (Form-ll) of 3R,4S,5S,6R,7R,9R,11S,12R,13S,14R-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-1-oxa-cyclotetradecan-2-one or roxithromycin having at least one characteristic infra-red spectrum peak at approximately 3580 to 3464 cm | 02-21-2013 |
20130039987 | METHOD FOR INCREASING THE SOLUBILITY OF A TRANSCRIPTASE INHIBITOR COMPOSITION - The invention provides a method for increasing the solubility of nevirapine, including the steps of rendering nevirapine in a gaseous phase; and rendering the gaseous phase in a relatively more soluble solid particulate form. The invention further provides for a crystalline Form-VI ( | 02-14-2013 |
20120302442 | PLANT SUPPORT FORMULATION, VEHICLE FOR THE DELIVERY AND TRANSLOCATION OF PHYTOLOGICALLY BENEFICIAL SUBSTANCES AND COMPOSITIONS CONTAINING SAME - A plant supporting formulation which is also suitable for use as a delivery vehicle, or a component of a delivery vehicle, for the delivery of one or more phytologically beneficial substances to a plant, and for enhancing the translocation of such delivered substance(s) in or on the plant, the formulation comprising a micro-emulsion constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous carrier, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. The dispersion is preferably characterized in that at least 50% of the vesicles or microsponges are of a diametrical size of between 50 nm and 5 micrometer. The dispersion is further also characterized in that the micro-emulsion has a zeta potential of between −25 mV and −60 mV. | 11-29-2012 |
20120192624 | Ignition System - An ignition system ( | 08-02-2012 |
20100297249 | ENHANCEMENT OF THE EFFICACY OF THERAPEUTIC PROTEINS - The invention provides a formulation for the administration of at least one therapeutic mammalian protein to a mammal, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, the formulation consisting of at least one therapeutic mammalian protein in a micro-emulsion which micro-emulsion is constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous or other pharmacologically acceptable earner in which nitrous oxide is dissolved, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids It further provides a method of the effective delivery of at least one therapeutic mammalian protein to a mammal and for enhancing the therapeutic efficacy of such at least one therapeutic mammalian protein, the method comprising the step of administering the at least one therapeutic mammalian protein to the mammal in such a formulation | 11-25-2010 |
20100099734 | AMINO ACID AND ITS USES - This invention relates to a supplement, the use thereof and method for supplementing the concentration of free cellular L-proline in an organism, for restricting dehydration of such an organism, the supplement comprising an effective amount of free L-proline. The supplement is effective in reducing the levels of free radicals in organisms experiencing water stress. This invention further relates to a method of treating dehydration in humans and animals including the step of administering to an individual in need thereof an effective amount of a supplement according to the third aspect of the invention. An effective amount of free L-proline is typically between 20 and 1000 mg, preferably 100 mg free L-proline per kilogram body mass of the organism, three times a day. | 04-22-2010 |
20090272328 | Uses of Amino Acid and Amino Acid Supplements Thereof - This invention relates to the use of free L-proline in the preparation of a supplement, and to a supplement so prepared, as well as a method using such a supplement for supplementing the concentration of cellular free L-proline in abalone and for restricting the dehydration of abalone. The supplement is further effective in reducing the levels of free radicals in abalone experiencing water stress and hypoxic stress. The invention further relates to a method of restricting the dehydration of abalone during storage and transportation including the step of administering to abalone an effective amount of free L-proline. | 11-05-2009 |
20090192040 | PLANT SUPPORT FORMULATION, VEHICLE FOR THE DELIVERY AND TRANSLOCATION OF PHYTOLOGICALLY BENEFICAL SUBSTANCES AND COMPOSITIONS CONTAINING SAME - The invention provides a plant supporting formulation which is also suitable for use as a delivery vehicle, or a component of a delivery vehicle, for the delivery of one or more phytologically beneficial substances to a plant, and for enhancing the translocation of such delivered substance(s) in or on the plant, the formulation comprising a micro-emulsion constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous carrier, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. The dispersion is preferably characterized in that at least 50% of the vesicles or microsponges are of a diametrical size of between 50 nm and 5 micrometers. The dispersion is further also characterized in that the micro-emulsion has a zeta potential of between −25 mV and −60 mV | 07-30-2009 |
20090188458 | IGNITION SYSTEM - An ignition system ( | 07-30-2009 |
20080203457 | FAST SWITCHING POWER INSULATED GATE SEMICONDUCTOR DEVICE - An insulated gate semiconductor device ( | 08-28-2008 |